Glycopyrronium (PT001) vs Oxitropium bromide (Ba253BINEB)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Glycopyrronium (PT001)
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
Next expected readout: May 2029 · NCT07525375 (registry estimate)
Reported efficacy
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)
Result source: NCT03358147
Oxitropium bromide (Ba253BINEB)
Developed by Boehringer Ingelheim
NCT02182661 · Phase 3 · completed
The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrronium (PT001) | Oxitropium bromide (Ba253BINEB) |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not posted · NCT02182661 |
| Trough FEV1, change | 0.1 vs 0.1±0 vs placeboNCT033581472 other results
| —Not posted · NCT02182661 |
| ACQ-5, change | -0.9 vs -0.9+0.1 vs placeboNCT033581472 other results
| —Not posted · NCT02182661 |
| OCS dose reduction | —Not reported | —Not posted · NCT02182661 |
Severe exacerbations, annualised rate
- Glycopyrronium (PT001)
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
Trough FEV1, change
- Glycopyrronium (PT001)
- 0.1 vs 0.1±0 vs placeboNCT03358147
2 other results
- 0.1 vs 0.1 NCT03358147
- 0.1 vs 0.1 NCT03358147
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
ACQ-5, change
- Glycopyrronium (PT001)
- -0.9 vs -0.9+0.1 vs placeboNCT03358147
2 other results
- -0.8 vs -0.9 NCT03358147
- -1.0 vs -0.9 NCT03358147
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
OCS dose reduction
- Glycopyrronium (PT001)
- —Not reported
- Oxitropium bromide (Ba253BINEB)
- —Not posted · NCT02182661
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Glycopyrronium (PT001): 4 of 4 rows · Oxitropium bromide (Ba253BINEB): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrronium (PT001) |
|---|---|
| Dropout rate | 14.5%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results16.3%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 14.2%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Discontinued due to AEs | 1.3%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results3.8%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.9%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Serious AEs | 3.8%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results2.9%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.5%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
| Most frequent reported AEs | 28.8 μg upper respiratory tract infection 6% (placebo 8%) nasopharyngitis 4.7% (placebo 3.4%) sinusitis 4.3% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results14.4 μg nasopharyngitis 6.3% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 2.9% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 7.2 μg nasopharyngitis 7.1% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 1.7% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrronium (PT001)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Oxitropium bromide (Ba253BINEB)'s landscape